Elicera Therapeutics AB (publ) (STO:ELIC)

Market Cap	165.51M -53.8%
Revenue (ttm)	10.64M +146.7%
Net Income	-14.45M
EPS	-0.30
Shares Out	66.74M
PE Ratio	n/a
Forward PE	36.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	385,543
Open	2.450
Previous Close	2.480
Day's Range	2.405 - 2.590
52-Week Range	2.255 - 8.430
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ELIC

Financial Performance

In 2025, Elicera Therapeutics AB's revenue was 10.86 million, an increase of 52.28% compared to the previous year's 7.13 million. Losses were -17.41 million, 8.05% more than in 2024.